Skip to main content
Top
Published in:

Open Access 01-12-2024 | Prostate Cancer | Research

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study

Authors: E Wu, Guo-Fang Wei, Yang Li, Meng-Kai Du, Jun-Tao Ni

Published in: BMC Medicine | Issue 1/2024

Login to get access

Abstract

Background

The relationship between serum urea concentration and cancer in patients with metabolic syndrome (MetS) remains unclear. This study aimed to investigate the association between serum urea concentration and 16 site-specific cancers, overall cancer incidence, and cancer mortality in individuals with MetS.

Methods

We analysed the data of 108,284 individuals with MetS obtained from the UK Biobank. The Cox proportional hazards model was used to determine the association between serum urea concentration at recruitment and cancer. The Benjamini–Hochberg correction was used to account for multiple comparisons.

Results

Over the median follow-up period of 11.86 years, 18,548 new incident cases of cancer were documented. There were inverse associations of urea concentration with overall cancer incidence, and the incidence of oesophageal and lung cancers, with respective hazard ratios (95% confidence intervals) [HR (95% CI)] for the highest (Q4) vs lowest (Q1) urea quartiles of 0.95 (0.91–0.99), 0.68 (0.50–0.92), and 0.76 (0.64–0.90). However, high serum urea concentrations increased the male prostate cancer risk (HR 1.15; 95% CI 1.02–1.30). Although the Cox model indicated a protective effect of higher urea levels against stomach (HR 0.67; 95% CI 0.45–0.98; p = 0.040; FDR 0.120) and colorectal cancer (HR 0.86; 95% CI 0.74–0.99; p = 0.048; FDR 0.123), no strong evidence of association was found after applying the Benjamin-Hochberg correction. Moreover, across the median follow-up period of 13.77 years for cancer mortality outcome, 5034 cancer deaths were detected. An “L-shaped” nonlinear dose–response relationship between urea concentration and cancer mortality was discovered (p-nonlinear < 0.001), and the HR (95% CI) for urea concentration Q4 vs Q1 was 0.83 (0.77–0.91).

Conclusions

Serum urea concentration can be considered as a valuable biomarker for evaluating cancer risk in individuals with MetS, potentially contributing to personalised cancer screening and management strategies.
Appendix
Available only for authorised users
Literature
3.
go back to reference Peiris CL, van Namen M, O'Donoghue G. Education-based, lifestyle intervention programs with unsupervised exercise improve outcomes in adults with metabolic syndrome. A systematic review and meta-analysis. Rev Endocr Metab Disord. 2021;22(4):877–890. https://doi.org/10.1007/s11154-021-09644-2. Peiris CL, van Namen M, O'Donoghue G. Education-based, lifestyle intervention programs with unsupervised exercise improve outcomes in adults with metabolic syndrome. A systematic review and meta-analysis. Rev Endocr Metab Disord. 2021;22(4):877–890. https://​doi.​org/​10.​1007/​s11154-021-09644-2.
17.
25.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/circulationaha.109.192644.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://​doi.​org/​10.​1161/​circulationaha.​109.​192644.CrossRefPubMed
26.
go back to reference Fry D AR, Moffat S, Gordon M, Singh P. UK Biobank Biomarker Project: Companion Document to Accompany Serum Biomarker Data, Version 1.0. Stockport: UK Biobank. 2019. Fry D AR, Moffat S, Gordon M, Singh P. UK Biobank Biomarker Project: Companion Document to Accompany Serum Biomarker Data, Version 1.0. Stockport: UK Biobank. 2019.
29.
go back to reference Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int J Epidemiol. 2023;52(1):71–86. https://doi.org/10.1093/ije/dyac124.CrossRefPubMed Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int J Epidemiol. 2023;52(1):71–86. https://​doi.​org/​10.​1093/​ije/​dyac124.CrossRefPubMed
32.
go back to reference Daniels B, Kiely BE, Houssami N, Lord SJ, Dobbins T, Lu CY, et al. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014). Br J Cancer. 2018;118(3):441–7.CrossRefPubMed Daniels B, Kiely BE, Houssami N, Lord SJ, Dobbins T, Lu CY, et al. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014). Br J Cancer. 2018;118(3):441–7.CrossRefPubMed
35.
go back to reference Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.CrossRef Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.CrossRef
44.
go back to reference Kurasawa S, Imaizumi T, Maruyama S, Tanaka K, Kubo Y, Nagayoshi M, et al. Association of kidney function with cancer incidence and its influence on cancer risk of smoking: The Japan Multi-Institutional Collaborative Cohort Study. Int J Cancer. 2023;153(4):732–41. https://doi.org/10.1002/ijc.34554.CrossRefPubMed Kurasawa S, Imaizumi T, Maruyama S, Tanaka K, Kubo Y, Nagayoshi M, et al. Association of kidney function with cancer incidence and its influence on cancer risk of smoking: The Japan Multi-Institutional Collaborative Cohort Study. Int J Cancer. 2023;153(4):732–41. https://​doi.​org/​10.​1002/​ijc.​34554.CrossRefPubMed
47.
go back to reference Oppenheim JJ, Fishbein WN. Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Can Res. 1965;25(7):980–5. Oppenheim JJ, Fishbein WN. Induction of chromosome breaks in cultured normal human leukocytes by potassium arsenite, hydroxyurea and related compounds. Can Res. 1965;25(7):980–5.
Metadata
Title
Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study
Authors
E Wu
Guo-Fang Wei
Yang Li
Meng-Kai Du
Jun-Tao Ni
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2024
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-024-03758-5

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more